Want to see HK:2096 full AI Analyst Report?
Simcere Pharmaceutical Group Limited (2096) Ratios
4 Followers
Simcere Pharmaceutical Group Limited Ratios
HK:2096's free cash flow for Q2 2026 was ¥1.35B. For the 2026 fiscal year, HK:2096's free cash flow was decreased by ¥-253.23M and operating cash flow was ¥1.61B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.21 | 2.00 | 2.10 | 1.84 | 1.63 |
| Quick Ratio | 2.03 | 1.79 | 1.81 | 1.74 | 1.55 |
| Cash Ratio | 1.06 | 0.71 | 0.75 | 0.56 | 0.32 |
| Solvency Ratio | 0.32 | 0.21 | 0.28 | 0.31 | 0.46 |
| Operating Cash Flow Ratio | 0.60 | 0.51 | 0.06 | 0.46 | -0.07 |
| Short-Term Operating Cash Flow Coverage | 1.91 | 1.32 | 0.15 | 1.05 | -0.13 |
| Net Current Asset Value | ¥ 2.08B | ¥ 1.02B | ¥ 2.01B | ¥ 1.82B | ¥ 1.28B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.11 | 0.13 | 0.14 | 0.16 |
| Debt-to-Equity Ratio | 0.13 | 0.17 | 0.20 | 0.21 | 0.25 |
| Debt-to-Capital Ratio | 0.11 | 0.15 | 0.17 | 0.17 | 0.20 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.57 | 1.63 | 1.50 | 1.51 | 1.58 |
| Debt Service Coverage Ratio | 1.42 | 1.13 | 1.01 | 0.65 | 0.32 |
| Interest Coverage Ratio | 16.24 | 12.19 | 20.59 | 25.07 | 20.45 |
| Debt to Market Cap | 0.04 | 0.06 | 0.08 | 0.05 | 0.08 |
| Interest Debt Per Share | 0.52 | 0.51 | 0.55 | 0.59 | 0.65 |
| Net Debt to EBITDA | -1.31 | -0.54 | -0.53 | -0.19 | 1.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.61% | 80.25% | 75.43% | 79.08% | 78.40% |
| EBIT Margin | 18.33% | 17.12% | 11.72% | 9.60% | 4.67% |
| EBITDA Margin | 23.26% | 20.35% | 16.41% | 12.90% | 8.45% |
| Operating Profit Margin | 20.12% | 12.78% | 10.77% | 13.65% | 28.97% |
| Pretax Profit Margin | 19.59% | 12.36% | 11.20% | 14.06% | 28.04% |
| Net Profit Margin | 17.38% | 11.05% | 10.82% | 14.73% | 30.14% |
| Continuous Operations Profit Margin | 17.38% | 11.05% | 10.80% | 14.67% | 29.98% |
| Net Income Per EBT | 88.75% | 89.42% | 96.58% | 104.81% | 107.51% |
| EBT Per EBIT | 97.35% | 96.68% | 103.97% | 102.97% | 96.77% |
| Return on Assets (ROA) | 9.12% | 6.37% | 6.59% | 8.63% | 14.83% |
| Return on Equity (ROE) | 14.28% | 10.37% | 9.90% | 13.06% | 23.41% |
| Return on Capital Employed (ROCE) | 13.66% | 9.66% | 8.71% | 11.03% | 20.41% |
| Return on Invested Capital (ROIC) | 11.05% | 7.66% | 7.41% | 9.41% | 16.73% |
| Return on Tangible Assets | 10.22% | 7.09% | 7.15% | 9.10% | 15.18% |
| Earnings Yield | 5.02% | 4.35% | 4.54% | 3.47% | 7.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.61 | 2.45 | 2.50 | 2.52 | 2.08 |
| Payables Turnover | 5.91 | 4.75 | 5.12 | 3.94 | 3.33 |
| Inventory Turnover | 2.41 | 2.21 | 2.11 | 4.34 | 4.59 |
| Fixed Asset Turnover | 3.05 | 2.92 | 3.04 | 2.91 | 2.55 |
| Asset Turnover | 0.52 | 0.58 | 0.61 | 0.59 | 0.49 |
| Working Capital Turnover Ratio | 2.28 | 2.33 | 2.43 | 2.87 | 2.05 |
| Cash Conversion Cycle | 229.58 | 237.62 | 247.90 | 136.21 | 145.11 |
| Days of Sales Outstanding | 139.94 | 149.08 | 146.08 | 144.67 | 175.12 |
| Days of Inventory Outstanding | 151.42 | 165.33 | 173.13 | 84.13 | 79.48 |
| Days of Payables Outstanding | 61.78 | 76.79 | 71.31 | 92.59 | 109.49 |
| Operating Cycle | 291.36 | 314.41 | 319.21 | 228.81 | 254.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.81 | 0.55 | 0.06 | 0.52 | -0.08 |
| Free Cash Flow Per Share | 0.46 | 0.25 | -0.31 | 0.26 | -0.16 |
| Dividend Paid and CapEx Coverage Ratio | 1.61 | 1.20 | 0.11 | 1.27 | -0.34 |
| Capital Expenditure Coverage Ratio | 2.34 | 1.82 | 0.15 | 2.00 | -0.96 |
| Operating Cash Flow Coverage Ratio | 1.68 | 1.15 | 0.11 | 0.90 | -0.12 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.21 | 0.02 | 0.21 | -0.04 |
| Free Cash Flow Yield | 4.30% | 3.73% | -5.27% | 2.53% | -2.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 19.91 | 22.99 | 22.01 | 28.78 | 12.67 |
| Price-to-Sales (P/S) Ratio | 3.46 | 2.54 | 2.38 | 4.24 | 3.82 |
| Price-to-Book (P/B) Ratio | 2.84 | 2.39 | 2.18 | 3.76 | 2.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 23.24 | 26.82 | -18.99 | 39.59 | -46.42 |
| Price-to-Operating Cash Flow Ratio | 13.29 | 12.12 | 104.18 | 19.78 | -94.56 |
| Price-to-Earnings Growth (PEG) Ratio | 0.23 | 3.10 | -0.88 | -0.76 | 0.10 |
| Enterprise Value Multiple | 13.57 | 11.94 | 13.98 | 32.67 | 46.78 |
| Enterprise Value | 24.40B | 16.12B | 15.16B | 26.64B | 19.76B |
| EV to EBITDA | 13.57 | 11.94 | 13.98 | 32.67 | 46.78 |
| EV to Sales | 3.16 | 2.43 | 2.29 | 4.22 | 3.95 |
| EV to Free Cash Flow | 21.19 | 25.65 | -18.29 | 39.37 | -48.03 |
| EV to Operating Cash Flow | 12.12 | 11.59 | 100.35 | 19.67 | -97.85 |
| Tangible Book Value Per Share | 3.15 | 2.33 | 2.40 | 2.52 | 2.39 |
| Shareholders’ Equity Per Share | 3.78 | 2.80 | 2.73 | 2.73 | 2.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.11 | 0.04 | -0.05 | -0.07 |
| Revenue Per Share | 3.11 | 2.62 | 2.50 | 2.42 | 1.92 |
| Net Income Per Share | 0.54 | 0.29 | 0.27 | 0.36 | 0.58 |
| Tax Burden | 0.89 | 0.89 | 0.97 | 1.05 | 1.08 |
| Interest Burden | 1.07 | 0.72 | 0.96 | 1.46 | 6.01 |
| Research & Development to Revenue | 0.20 | 0.21 | 0.24 | 0.27 | 0.28 |
| SG&A to Revenue | 0.45 | 0.46 | 0.07 | 0.07 | 0.08 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.00 | 0.02 | 0.01 |
| Income Quality | 1.33 | 1.70 | 0.20 | 1.53 | -0.14 |
Currency in CNY
